201 related articles for article (PubMed ID: 24037835)
1. Therapeutic human monoclonal antibodies in inflammatory diseases.
Kotsovilis S; Andreakos E
Methods Mol Biol; 2014; 1060():37-59. PubMed ID: 24037835
[TBL] [Abstract][Full Text] [Related]
2. Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases. I. Immunology and therapeutic potential of antiadhesion molecule therapy in inflammatory bowel disease.
Van Assche G; Rutgeerts P
Am J Physiol Gastrointest Liver Physiol; 2005 Feb; 288(2):G169-74. PubMed ID: 15647604
[TBL] [Abstract][Full Text] [Related]
3. Anti-TNF agents for the treatment of psoriasis.
Kircik LH; Del Rosso JQ
J Drugs Dermatol; 2009 Jun; 8(6):546-59. PubMed ID: 19537380
[TBL] [Abstract][Full Text] [Related]
4. Anti-TNF-alpha treatment strategies: results and clinical perspectives.
D'Haens G
Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S209-16. PubMed ID: 20117344
[TBL] [Abstract][Full Text] [Related]
5. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions.
Sfikakis PP
Curr Dir Autoimmun; 2010; 11():180-210. PubMed ID: 20173395
[TBL] [Abstract][Full Text] [Related]
6. Tumor necrosis factor-α monoclonal antibodies in the treatment of inflammatory bowel disease: clinical practice pharmacology.
Lee TW; Fedorak RN
Gastroenterol Clin North Am; 2010 Sep; 39(3):543-57. PubMed ID: 20951917
[TBL] [Abstract][Full Text] [Related]
7. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
[TBL] [Abstract][Full Text] [Related]
8. Adalimumab in the treatment of rheumatoid arthritis.
Voulgari PV; Kaltsonoudis E; Papagoras C; Drosos AA
Expert Opin Biol Ther; 2012 Dec; 12(12):1679-86. PubMed ID: 22954150
[TBL] [Abstract][Full Text] [Related]
9. [Monoclonal antibodies in chronic autoimmune inflammatory diseases].
Semerano L; Boissier MC
Med Sci (Paris); 2009 Dec; 25(12):1108-12. PubMed ID: 20035687
[TBL] [Abstract][Full Text] [Related]
10. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms.
Ordás I; Mould DR; Feagan BG; Sandborn WJ
Clin Pharmacol Ther; 2012 Apr; 91(4):635-46. PubMed ID: 22357456
[TBL] [Abstract][Full Text] [Related]
11. Emerging biological treatments in inflammatory bowel diseases.
Van Assche G; Vermeire S; Rutgeerts P
Dig Dis; 2006; 24(1-2):131-6. PubMed ID: 16699271
[TBL] [Abstract][Full Text] [Related]
12. [New therapy in inflammatory bowel disease (infliximab)].
Yoshizawa S; Hibi T
Nihon Rinsho; 2008 Jul; 66(7):1279-85. PubMed ID: 18616118
[TBL] [Abstract][Full Text] [Related]
13. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics.
Papoutsaki M; Chimenti MS; Costanzo A; Talamonti M; Zangrilli A; Giunta A; Bianchi L; Chimenti S
J Am Acad Dermatol; 2007 Aug; 57(2):269-75. PubMed ID: 17574299
[TBL] [Abstract][Full Text] [Related]
14. IBD in 2013: enriching the therapeutic armamentarium for IBD.
Danese S; Peyrin-Biroulet L
Nat Rev Gastroenterol Hepatol; 2014 Feb; 11(2):84-6. PubMed ID: 24366229
[TBL] [Abstract][Full Text] [Related]
15. Methotrexate for psoriasiform lesions associated with anti-tumour necrosis factor therapy in inflammatory bowel disease.
Buisson A; Cuny JF; Barbaud A; Schmutz JL; Bigard MA; Guéant JL; Peyrin-Biroulet L
Aliment Pharmacol Ther; 2012 May; 35(10):1175-80. PubMed ID: 22469155
[TBL] [Abstract][Full Text] [Related]
16. Anti-TNF therapy in inflammatory bowel diseases: a huge review.
Peyrin-Biroulet L
Minerva Gastroenterol Dietol; 2010 Jun; 56(2):233-43. PubMed ID: 20485259
[TBL] [Abstract][Full Text] [Related]
17. Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-α therapy during pregnancy: three-center study.
Bortlik M; Machkova N; Duricova D; Malickova K; Hrdlicka L; Lukas M; Kohout P; Shonova O; Lukas M
Scand J Gastroenterol; 2013 Aug; 48(8):951-8. PubMed ID: 23834232
[TBL] [Abstract][Full Text] [Related]
18. [Perspectives in inflammatory bowel diseases treatment].
Jalocha L; Wojtuń S; Dyrla P; Błaszak A; Wojtkowiak M; Zyśko B; Stelmaszuk T; Gil J
Pol Merkur Lekarski; 2009 May; 26(155):556-8. PubMed ID: 19606725
[TBL] [Abstract][Full Text] [Related]
19. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review.
Tracey D; Klareskog L; Sasso EH; Salfeld JG; Tak PP
Pharmacol Ther; 2008 Feb; 117(2):244-79. PubMed ID: 18155297
[TBL] [Abstract][Full Text] [Related]
20. Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases.
Danese S; Panés J
Gastroenterology; 2014 Nov; 147(5):981-9. PubMed ID: 25220794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
